Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy
- PMID: 19616668
- DOI: 10.1016/j.amjcard.2009.03.042
Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy
Abstract
Reversal of left ventricular (LV) hypertrophy is an important goal of antihypertensive therapy. This phase 3b study compared the ability of the angiotensin receptor blocker olmesartan medoxomil with the calcium channel blocker amlodipine besylate to induce regression of LV hypertrophy and vascular hypertrophy after achieving blood pressure (BP) goal. After a washout phase, 102 patients with hypertension and LV hypertrophy were randomized to olmesartan medoxomil 20 mg/day, up titrated to 40 mg/day, or amlodipine 5 mg/day, up titrated to 10 mg/day, for up to 4 weeks until a BP goal of <140/90 mm Hg (<130/85 mm Hg for diabetes) was achieved (hydrochlorothiazide 25 mg/day and terazosin 1 to 5 mg/day 2 times/day could be added if needed). Upon achieving the BP goal or by week 8, and again at weeks 26 and 52, assessments of LV mass and compliance and arterial structure and function were performed by echocardiography, Doppler flow, and arterial ultrasonography, respectively. There was no statistically significant percent change in LV mass at 52 weeks in either treatment group (11.6% with olmesartan medoxomil vs 2.9% with amlodipine) and no statistically significant difference between treatment groups. There were no significant changes in LV compliance or carotid or femoral artery wall-to-lumen ratios in either treatment group at 52 weeks. In conclusion, there did not appear to be a clinically significant BP-independent effect with olmesartan medoxomil or amlodipine on LV mass decrease, diastolic function or vascular structure, and compliance in patients with hypertension and LV hypertrophy.
Similar articles
-
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.Blood Press Monit. 2006 Jun;11(3):135-41. doi: 10.1097/01.mbp.0000209087.40117.b3. Blood Press Monit. 2006. PMID: 16702822 Clinical Trial.
-
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.Am J Cardiovasc Drugs. 2007;7(5):361-72. doi: 10.2165/00129784-200707050-00006. Am J Cardiovasc Drugs. 2007. PMID: 17953475 Clinical Trial.
-
Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.J Am Coll Cardiol. 2007 Sep 18;50(12):1144-9. doi: 10.1016/j.jacc.2007.06.013. Epub 2007 Sep 4. J Am Coll Cardiol. 2007. PMID: 17868805
-
A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies.Am J Cardiovasc Drugs. 2006;6(2):103-13. doi: 10.2165/00129784-200606020-00004. Am J Cardiovasc Drugs. 2006. PMID: 16555863 Review.
-
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.Ther Adv Cardiovasc Dis. 2011 Oct;5(5):241-73. doi: 10.1177/1753944711420464. Epub 2011 Sep 5. Ther Adv Cardiovasc Dis. 2011. PMID: 21893558 Review.
Cited by
-
Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential.Nat Rev Cardiol. 2023 May;20(5):347-363. doi: 10.1038/s41569-022-00806-6. Epub 2023 Jan 4. Nat Rev Cardiol. 2023. PMID: 36596855 Free PMC article. Review.
-
Adverse events associated with amlodipine: a pharmacovigilance study using the FDA adverse event reporting system.Front Cardiovasc Med. 2025 May 6;12:1504671. doi: 10.3389/fcvm.2025.1504671. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40395720 Free PMC article.
-
Development of a novel 96-microwell assay with high throughput for determination of olmesartan medoxomil in its tablets.Chem Cent J. 2012 Jan 3;6:1. doi: 10.1186/1752-153X-6-1. Chem Cent J. 2012. PMID: 22214530 Free PMC article.
-
Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination.Integr Blood Press Control. 2010;3:155-62. doi: 10.2147/IBPC.S6662. Epub 2010 Nov 16. Integr Blood Press Control. 2010. PMID: 21949631 Free PMC article.
-
Impact of amlodipine on clinical outcomes for heart failure in patients with dilated cardiomyopathy: a Korean nationwide cohort study.Front Cardiovasc Med. 2023 Nov 17;10:1305824. doi: 10.3389/fcvm.2023.1305824. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 38045912 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical